Results 131 to 140 of about 68,419 (288)
Rare primary mediastinal masses
, 1993 Primer mediastinal karsinamalar ve primer mediastinal karsinoid tümörler mediasten kitleleri içinde oldukça nadirdirler. Biz son 15 yıl içinde primer mediastinal kitlesi olan 44 vaka tedavi ettik Bu 44 vaka içinde sadece bir primer mediastinal karsinoma ...
core
Impaired hematopoiesis affects apheresis and CAR T‐cell product composition and treatment response
Transfusion, EarlyView.Abstract Background Chimeric antigen receptor (CAR) T‐cell therapy has transformed the treatment of hematologic malignancies, but its success depends on obtaining sufficient CD3+ T‐cell yields during leukapheresis. This can be difficult in heavily pretreated patients, who often show leukopenia and reduced T‐cell fitness.
Hanna Kuhn +14 more
wiley +1 more source
Mediastinal cystic lymphangioma Linfangioma cístico do mediastino
Revista Portuguesa de Pneumologia, 2006 Mediastinal lymphangioma is a rare vascular neoplasm, accounting for 0.7 to 4.5% of all the mediastinum tumors. It is a benign tumor, generally occurring as a mediastinal mass of slow growth.
Sandra Saleiro +3 more
doaj
International Journal of Cancer, Volume 159, Issue 4, Page 985-996, 15 August 2026.The optimal timing of surgery after neoadjuvant immunochemotherapy (NICT) for locally advanced non‐small cell lung cancer (NSCLC) remains unclear. In this retrospective investigation, the impact of time interval on outcome was assessed among NSCLC patients who completed NICT before undergoing radical resection.
Jiayi Wang +12 more
wiley +1 more source
Primary Mediastinal Myelolipoma
, 2008 Myelolipoma is a rare mesenchymal tumor composed of an admixture of fat and bone marrow-derived hematopoietic cells. It is typically an adrenal lesion, and mediastinal location is extremely unusual. We describe a 56-year-old man with nonspecific symptoms
Sadeghipour, A. +3 more
core
Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.ABSTRACT Objective To evaluate selumetinib exposure using therapeutic drug monitoring (TDM) in pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibromas (PN), assess interpatient pharmacokinetic variability, and explore the relationship between drug exposure, clinical response, and adverse effects.
Janka Kovács +8 more
wiley +1 more source
Outcomes of Live Virus Vaccination in Patients With Vascular Anomalies Being Treated With Sirolimus
Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.ABSTRACT Background Live vaccination in patients with vascular anomalies (VA) receiving sirolimus remains controversial due to immunosuppressive effects and theoretical risks. Procedure This single‐center retrospective study included patients with VA less than 4 years old at the start of sirolimus therapy who were incompletely vaccinated.
Svatava Merkle +5 more
wiley +1 more source